Kyverna Therapeutics, Inc. (KYTX)

Market Cap	424.25M
Revenue (ttm)	n/a
Net Income (ttm)	-75.92M
Shares Out	43.12M
EPS (ttm)	-1.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	294,923
Open	9.02
Previous Close	8.90
Day's Range	8.81 - 10.07
52-Week Range	6.75 - 30.60
Beta	n/a
Analysts	Buy
Price Target	29.00 (+194.72%)
Earnings Date	Aug 12, 2024

About KYTX

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 8, 2024
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: KYTX

Analyst Forecast

According to 3 analysts, the average rating for KYTX stock is "Buy." The 12-month stock price forecast is $29.0, which is an increase of 194.72% from the latest price.

Price Target

$29.0

(194.72% upside)

Analyst Consensus: Buy